DE:H7T2 Stock Latest News
Company AnnouncementsHUTCHMED’s Sovleplenib Wins US Orphan Drug Status for Rare Blood Disorder3d ago
Company AnnouncementsHUTCHMED to Showcase Savolitinib Lung Cancer Data in Investor Webcast5d ago
Company AnnouncementsHUTCHMED Combination Therapy Delivers Strong Phase III Lung Cancer Results6d ago
Company AnnouncementsHUTCHMED’s ORPATHYS Combo Delivers Phase III Survival Gains in MET-Driven Lung Cancer6d ago
Company AnnouncementsHUTCHMED Seals Global HMPL-A830 Licensing Deal With GSK Outside China1w agoCompany AnnouncementsHUTCHMED Backs AstraZeneca’s U.S. Filing for ORPATHYS–TAGRISSO Lung Cancer Combo1M ago
Company AnnouncementsHUTCHMED launches first-in-human global trial of novel KRAS-EGFR cancer therapy HMPL-A8301M ago
Company AnnouncementsHUTCHMED to showcase pivotal lung cancer and broad oncology data at ESMO 20261M ago
The FlyHutchmed upgraded to Buy from Hold at HSBC1M agoHCM- The FlyHutchmed rises 13.7%1M agoHCM
Company AnnouncementsHUTCHMED Licenses First-in-Class KRAS-EGFR Cancer Therapy to GSK in US$1.3 Billion Deal1M ago
Company AnnouncementsHUTCHMED’s ORPATHYS–TAGRISSO Combo Delivers First-Line PFS Gain in MET-Driven Lung Cancer2M ago
Company AnnouncementsHUTCHMED’s ORPATHYS Combo Delivers First-Line Benefit in MET-Driven Lung Cancer2M agoCompany AnnouncementsHUTCHMED Flags Director’s Link to Insolvent Israeli Medtech Firm, Sees No Impact2M ago